Benign Prostatic Hyperplasia

“Urologists tend to be early adopters of new technology. That said, how fast adoption of prostatic urethral lift has been in the urologic community was really impressive,” says Jonathan Shoag, MD.

“This study suggests that there is little difference in erectile dysfunction between the various treatments over 60-month follow-up,” says Peter Gilling, MD.

Plaintiff alleges injury occurred during insertion of Foley catheter.

“Clinicians should considerer these data when prescribing 5-ARIs to patients,” said Dr. Antonio Franco.

"Depending on the age of the surgeon, one may be surprised to hear that it was common to perform a vasectomy routinely on patients undergoing a TURP procedure," write Jonathan Rubenstein, MD, and Mark Painter.

“[These findings] provide intriguing insights into the etiology and genetic components of BPH,” said study author Joel T. Funk, MD.

A recently published study showed an increased risk of cardiac failure in men with BPH and exposure to 5-alpha reductase inhibitors and/or α-blockers.

MRI-guided transurethral ultrasound ablation (TULSA) demonstrated efficacy and safety as a treatment for patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

The UroLift System is a noninvasive treatment for patients with BPH that relieves prostate obstruction by lifting and holding the prostate tissue that is blocking the urethra.

Nearly half of the surveyed men reported that urinary symptoms led them to avoid events or activities they enjoy.

The primary outcome measure of the phase 3 ATHLETE study is the noninferiority of aquablation versus HoLEP in alleviating lower urinary tract symptoms related to benign prostatic obstruction.

In this interview, Alexis E. Te, MD, discusses the evolution of LUTS treatment, what primary care providers should include in their evaluation when seeing a patient with LUTS, and how he selects treatments for patients with BPH.

"Retreatment is the new buzz word and is very controversial, as parameters keep changing," writes Gopal H. Badlani, MD.

Tadfin is a once-daily capsule that combines 5 mg of tadalafil (Cialis) with 5 mg of finasteride (Proscar).

The test can help clinician determine whether a second procedure would be of benefit to a patient.

There were also no reports of sexual dysfunction related to device or procedure and no reported cases of sustained de novo erectile dysfunction at 5 years.

The Optilume drug-coated balloon catheter system is used to treat patients with lower urinary tract symptoms related to benign prostatic hyperplasia.

"Placing a catheter to irrigate obstructing blood clots (CPT 51700) is specifically included in the payment for the TURP if this complication is managed outside of an operating room," write Jonathan Rubenstein, MD, and Mark Painter.

Medical necessity must be documented on the chart in order to bill code.

“The take-home message is that for the appropriate patient, each of [these] technologies works well,” says Richard K. Lee, MD, MBA.

A procedural code is now available to hospitals in France enabling use of UroLift to treat men aged ≥50 years with symptoms of an enlarged prostate up to 100 cc.

The highest risk was observed in patients exposed to alpha blocker therapy alone.

Tadfin is a once-daily capsule that combines 5 mg of tadalafil (Cialis) with 5 mg of finasteride (Proscar).

The investigators also determined independent factors affecting the efficacy of vibegron in this setting.

The XFLO Expander System provided patients with symptom relief while preserving sexual function.

The risks of erectile dysfunction or rectourethral fistula post-cryosurgery were also not increased by prior surgical interventional therapy for benign prostatic hyperplasia.

Investigators reported that the treatment-emergent adverse event results showed combination tamsulosin and mirabegron was well-tolerated and had a favorable safety profile.

Holmium laser lithotripsy with Moses 2.0 is intended to enhance precision and versatility by optimizing laser energy transmission.

The drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.

Minimally invasive water vapor thermal therapy offers rapid improvements in LUTS, QoL, and flow rate that remain durable to 5 years in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.